Figure 1. During REP treatment, Ikaros and Aiolos levels can be modulated in lymphocytes from lenalidomide-refractory patients.

PBMCs obtained at the start of cycle 1 (C1D1), mid-cycle (C1D14) and start of cycle 2 (C2D1) were stained for CD3, CD4, CD8, CD19 and CD56 to identify the different lymphocyte subsets. Lymphocytes were then stained for intracellular Ikaros (A) and Aiolos (B) expression and analyzed by flow cytometry. (C) Correlation between baseline Ikaros and Aiolos expression levels in the different lymphocyte subsets. (D) Correlation between fold change from C1D1 to C1D14 in Ikaros and Aiolos expression in the different lymphocyte subsets. P-values were calculated using the Wilcoxon matched pairs, signed rank test. ^***P < 0.001, ^****P < 0.0001, N.S. not significant.